101 related articles for article (PubMed ID: 30977687)
1. A multicenter real-world study of bevacizumab in heavily pretreated malignant gliomas: clinical benefit is a plausible end point?
Villani V; Fabi A; Tanzilli A; Pasqualetti F; Lombardi G; Vidiri A; Gonnelli A; Molinari A; Cantarella M; Bellu L; Terrenato I; Carosi M; Maschio M; Telera SM; Carapella CM; Cognetti F; Paiar F; Zagonel V; Pace A
Future Oncol; 2019 May; 15(15):1717-1727. PubMed ID: 30977687
[No Abstract] [Full Text] [Related]
2. Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma.
Cha Y; Kim YJ; Lee SH; Kim TM; Choi SH; Kim DW; Park CK; Kim IH; Kim JH; Kim E; Choi B; Kim CY; Kim IA; Heo DS
Cancer Res Treat; 2017 Jan; 49(1):129-140. PubMed ID: 27188199
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of bevacizumab therapy in recurrent malignant gliomas in relation to the prior recurrence pattern or tumor location.
Matsuda M; Ishikawa E; Yamamoto T; Akutsu H; Takano S; Matsumura A
J Clin Neurosci; 2017 Jun; 40():115-119. PubMed ID: 28246006
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab Efficacy and Recurrence Pattern of Persistent and Metastatic Cervical Cancer.
Lee N; Kim SI; Lee M; Kim HS; Kim JW; Park NH; Song YS
In Vivo; 2019; 33(3):863-868. PubMed ID: 31028209
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab Use and the Risk of Arterial and Venous Thromboembolism in Patients with High-Grade Gliomas: A Nested Case-Control Study.
Lee I; Adimadhyam S; Nutescu EA; Zhou J; Asfaw AA; Sweiss KI; Patel PR; Calip GS
Pharmacotherapy; 2019 Sep; 39(9):921-928. PubMed ID: 31332810
[TBL] [Abstract][Full Text] [Related]
6. A retrospective study of bevacizumab for treatment of brainstem glioma with malignant features.
Moriya S; Ohba S; Adachi K; Nishiyama Y; Hayashi T; Nagahisa S; Kaito T; Nakae S; Hirose Y
J Clin Neurosci; 2018 Jan; 47():228-233. PubMed ID: 29050897
[TBL] [Abstract][Full Text] [Related]
7. Tolerability and Efficacy of Bevacizumab Monotherapy in Older Patients With Recurrent Ovarian Cancer.
Shintani D; Yoshida H; Yabuno A; Fujiwara K
In Vivo; 2020; 34(3):1451-1457. PubMed ID: 32354945
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of an adult patient with diffuse midline glioma employing olaparib combined with bevacizumab.
Wang Y; Xu J; Luo N; Qi C; Tao R
Invest New Drugs; 2021 Oct; 39(5):1432-1435. PubMed ID: 33851364
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of recurrent high-grade gliomas treated with bevacizumab: A preliminary report of 3D pseudocontinuous artery spin labeling.
Lyu Y; Liu S; You H; Hou B; Wang Y; Ma W; Feng F
J Magn Reson Imaging; 2017 Aug; 46(2):565-573. PubMed ID: 27902863
[TBL] [Abstract][Full Text] [Related]
10. Progression-Free Survival in Patients Receiving Chemotherapy Alone (C) or Chemotherapy with Bevacizumab (CB) for First-Line Treatment of KRAS Mutant Metastatic Colorectal Cancer in Community Oncology Settings.
Houts AC; Ogale S; Zafar Y; Hubbard JM; Satram-Hoang S; Sommer N; Walker MS
J Gastrointest Cancer; 2019 Mar; 50(1):16-22. PubMed ID: 29058260
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter?
Palmer JD; Bhamidipati D; Song A; Eldredge-Hindy HB; Siglin J; Dan TD; Champ CE; Zhang I; Bar-Ad V; Kim L; Glass J; Evans JJ; Andrews DW; Werner-Wasik M; Shi W
J Neurooncol; 2018 Dec; 140(3):623-628. PubMed ID: 30182159
[TBL] [Abstract][Full Text] [Related]
12. Real-world use of bevacizumab in metastatic colorectal, metastatic breast, advanced ovarian and cervical cancer: a systematic literature review.
Raouf S; Bertelli G; Ograbek A; Field P; Tran I
Future Oncol; 2019 Feb; 15(5):543-561. PubMed ID: 30379088
[TBL] [Abstract][Full Text] [Related]
13. A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia.
Kay NE; Strati P; LaPlant BR; Leis JF; Nikcevich D; Call TG; Pettinger AM; Lesnick CE; Hanson CA; Shanafelt TD
Oncotarget; 2016 Nov; 7(48):78269-78280. PubMed ID: 27861157
[TBL] [Abstract][Full Text] [Related]
14. Reirradiation with concurrent bevacizumab for recurrent high-grade gliomas in adult patients.
Schernberg A; Dhermain F; Ammari S; Dumont SN; Domont J; Patrikidou A; Pallud J; Dezamis É; Deutsch É; Louvel G
Cancer Radiother; 2018 Feb; 22(1):9-16. PubMed ID: 29217134
[TBL] [Abstract][Full Text] [Related]
15. A predictive value of von Willebrand factor for early response to Bevacizumab therapy in recurrent glioma.
Pace A; Mandoj C; Antenucci A; Villani V; Sperduti I; Casini B; Carosi M; Fabi A; Vidiri A; Koudriavtseva T; Conti L
J Neurooncol; 2018 Jul; 138(3):527-535. PubMed ID: 29594657
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials.
Wu YS; Shui L; Shen D; Chen X
Oncotarget; 2017 Feb; 8(6):10703-10713. PubMed ID: 27793044
[TBL] [Abstract][Full Text] [Related]
17. Risk of Adverse Vascular Events in Patients with Malignant Glioma Treated with Bevacizumab Plus Irinotecan: A Systematic Review and Meta-Analysis.
Dong J; Meng X; Li S; Chen Q; Shi L; Jiang C; Cai J
World Neurosurg; 2019 Oct; 130():e236-e243. PubMed ID: 31203059
[TBL] [Abstract][Full Text] [Related]
18. PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma.
Kurz SC; Cabrera LP; Hastie D; Huang R; Unadkat P; Rinne M; Nayak L; Lee EQ; Reardon DA; Wen PY
Neurology; 2018 Oct; 91(14):e1355-e1359. PubMed ID: 30171077
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial.
Romera A; Peredpaya S; Shparyk Y; Bondarenko I; Mendonça Bariani G; Abdalla KC; Roca E; Franke F; Melo Cruz F; Ramesh A; Ostwal V; Shah P; Rahuman SA; Paravisini A; Huerga C; Del Campo García A; Millán S
Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):845-855. PubMed ID: 30262136
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab in Recurrent High-Grade Gliomas: A Canadian Retrospective Study.
Lim Fat MJ; Maurice C; Maganti M; Mason WP
Can J Neurol Sci; 2018 Jan; 45(1):56-61. PubMed ID: 29151389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
